To our knowledge, this is the first report analysing the available evidence for the use of anti-PD1/PDL1 checkpoint inhibitor immunotherapy in patients with Lynch syndrome for the treatment of colorectal cancer with MSS profile. This evidence concerns the gene PDCD1 and Lynch syndrome.